Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779476 | 1.00 | HRH3 (0.40) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL15328845 | 0.84 | KEAP1 (0.43) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL2441195 | 0.84 | KEAP1 (0.43) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL2441151 | 0.84 | KEAP1 (0.43) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL855030 | 0.83 | GNAI3 (0.40) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL20618432 | 0.83 | GNAI3 (0.44) | HRH3SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL856513 | 0.83 | GNAI3 (0.40) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL21584004 | 0.83 | GNAI3 (0.44) | HRH3SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL855029 | 0.83 | GNAI3 (0.40) | HRH3SIGMAR1L3MBTL1GNAI3GNAO1 | |
| SCHEMBL3771379 | 0.80 | HRH3 (0.45) | HRH3L3MBTL1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573092-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | Olema Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024039860-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |